What are the main competitors of cdmo in China?
Cdmo industry is a branch of pharmaceutical CXO industry, which can be divided into macromolecular cdmo industry and small molecule cdmo industry. Macromolecular cdmo is mainly biopharmaceutical, and small molecule cdmo industry is mainly chemical pharmacy.
Macromolecular cdmo intermediates are relatively unified, while small molecular chemicals are dispersed. There is a lack of standardized process in terms of production cycle, operation process and quality control, so it is difficult to count the market share.
In the macromolecular cdmo industry, Yaoming biology has an absolute leading position, with a market share of 79%. At the same time, its business scope covers all industrial chains. It is a unicorn enterprise in the macromolecular cdmo industry. Small molecule cdmo enterprises such as Pharmaron Beijing Co.Ltd(300759) , Asymchem Laboratories (Tianjin) Co.Ltd(002821) , Porton Pharma Solutions Ltd(300363) gradually develop large molecule cdmo business through investment, self construction, expansion and M & A.
01mah system drives cdmo industry development
Mah (marketing license holder) system: realize the separation of drug ownership and production right, allow pharmaceutical enterprises, R & D institutions or scholars to become drug marketing license holders, entrust other pharmaceutical enterprises to produce drugs, and bear the main legal responsibility for the quality of drug production and sales:
Mah helps cdmo / CMO enterprises to undertake more drug R & D and production orders, and mobilizes the power of innovative drug R & D institutions
Impact of 02cat-t therapy on cdmo industry
On June 22, 2021, China’s first car-t product was approved and Fosun Kate yikillunsai injection was listed. It is expected that China’s car-t market will begin to grow in 2021: it is expected that in the future, driven by the increase of cancer patients, preferential policies and the improvement of patients’ affordability, the market will grow to US $1.2 billion in 2025.
Cdm0 companies usually have large cell or carrier libraries, which can help pharmaceutical enterprises select suitable cells or carriers and optimize them, so as to reduce trial and error costs and improve the success rate of R & D.
Cdm0’s rich production platform and strict quality inspection measures can help pharmaceutical enterprises reduce the cost and time of commercial production. With the continuous maturity of CGT therapy, the CGT drug market will expand day by day. Therefore, the cgtcdm0 market will also rise and become a new wave of the development of the pharmaceutical industry.
